Gregory L. Shiferman - 24 Dec 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Senior Vice President, General Counsel and Secretary
Signature: /s/ Gregory Shiferman
Issuer symbol: SAGE
Transactions as of: 24 Dec 2024
Net transactions value: -$433
Form type: 4
Filing time: 27 Dec 2024, 16:11:56 UTC
Previous filing: 01 Nov 2024
Next filing: 21 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Tax liability	$433	-79	-0.4%	$5.48	19,888	24 Dec 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 24, 2024, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Content

On December 24, 2024, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Remarks:

Senior Vice President, General Counsel and Secretary